<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-DCI-2280</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-2427</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МАТЕРИАЛЫ ФОРУМА "ДНИ ИММУНОЛОГИИ В СПБ" 2021</subject></subj-group></article-categories><title-group><article-title>ДИНАМИКА БИОМАРКЕРОВ КАРДИОВАСКУЛЯРНОГО РИСКА И ЦИТОКИНОВ У БОЛЬНЫХ С ДЕКОМПЕНСИРОВАННОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ С СИСТОЛИЧЕСКОЙ ДИСФУНКЦИЕЙ ИШЕМИЧЕСКОГО ГЕНЕЗА ПРИ НАЛИЧИИ И ОТСУТСТВИИ МИОКАРДИТА</article-title><trans-title-group xml:lang="en"><trans-title>DYNAMIC CHANGES IN CARDIOVASCULAR RISK BIOMARKERS AND CYTOKINES OF MYOCARDITIS-FREE PATIENTS WITH DECOMPENSATED HEART FAILURE AND ISCHEMIC SYSTOLIC DYSFUNCTION</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Огуркова</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Ogurkova</surname><given-names>O. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., научный сотрудник отделения клинической лабораторной диагностики,</p><p>634012, г. Томск, ул. Киевская, 111а</p></bio><bio xml:lang="en"><p>PhD (Medicine), Research Associate, Department of Clinical Laboratory Diagnostics, </p><p>634012, Tomsk, Kievskaya str., 111a</p></bio><email xlink:type="simple">ogurkovaon@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кручинкина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kruchinkina</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>младший научный сотрудник отделения неотложной кардиологии,</p><p>634012, г. Томск, ул. Киевская, 111а</p></bio><bio xml:lang="en"><p>Junior Research Associate, Department of Emergency Cardiology,</p><p> </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гусакова</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Gusakova</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.фарм.н., научный сотрудник отделения клинической лабораторной диагностики, </p><p>634012, г. Томск, ул. Киевская, 111а</p></bio><bio xml:lang="en"><p>PhD (Pharmacology), Research Associate, Department of Clinical Laboratory Diagnostics,</p><p> </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Суслова</surname><given-names>Т. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Suslova</surname><given-names>T. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., руководитель отделения клинической лабораторной диагностики,</p><p>634012, г. Томск, ул. Киевская, 111а</p></bio><bio xml:lang="en"><p>PhD (Medicine), Head, Department of Clinical Laboratory Diagnostics, </p><p> </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рябов</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ryabov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., заместитель директора по научной и лечебной работе, 634012, г. Томск, ул. Киевская, 111а;</p><p>заведующий кафедрой кардиологии ФПК и ППС, г. Томск</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Deputy Director for Research and Clinical Services, 634012, Tomsk, Kievskaya str., 111a;</p><p>Head, Cardiology Department of the Continuous Medical Education Faculty, Tomsk</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Научно-исследовательский институт кардиологии ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук»<country>Россия</country></aff><aff xml:lang="en">Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Научно-исследовательский институт кардиологии ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук»;&#13;
ФГБОУ ВО «Сибирский государственный медицинский университет» Министерства здравоохранения РФ<country>Россия</country></aff><aff xml:lang="en">Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences;&#13;
Siberian State Medical University<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>18</day><month>10</month><year>2021</year></pub-date><volume>23</volume><issue>4</issue><fpage>839</fpage><lpage>844</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Огуркова О.Н., Кручинкина Е.В., Гусакова А.М., Суслова Т.Е., Рябов В.В., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Огуркова О.Н., Кручинкина Е.В., Гусакова А.М., Суслова Т.Е., Рябов В.В.</copyright-holder><copyright-holder xml:lang="en">Ogurkova O.N., Kruchinkina E.V., Gusakova A.M., Suslova T.E., Ryabov V.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/2427">https://www.mimmun.ru/mimmun/article/view/2427</self-uri><abstract><p>Развитие и прогрессирование сердечной недостаточности связано с различными патофизиологическими механизмами, особый интерес представляет изучение воспалительной реакции, как фундаментального звена в патогенезе ХСН и ее основного компонента – декомпенсации. Проведено открытое, нерандомизированное, проспективное исследование по изучению клинико-морфологических особенностей субклинического воспаления у больных с острой декомпенсацией ишемической хронической сердечной недостаточностью со сниженной фракцией выброса. В исследование были включены 25 больных с декомпенсацией ишемической ХСН с ФВ левого желудочка &lt; 40% в возрасте от 35 до 75 лет (60,12±9,3) с подписанным информированным согласием. В данном исследовании изучалась динамика содержания в сыворотке крови С-реактивного белка (СРБ), N-концевого фрагмента белка-предшественника мозгового натрийуретического пептида (NT-proBNP), растворимого ST2 (sST2), рецептора инсулиноподобного фактора роста 1 (IGF-1R), интерлейкина-6 (IL-6), интерлейкина-10 (IL-10), фактора некроза опухоли-α (TNFa) на Multiplex Instrument FLEXMAP 3D Luminex Corporation. Все обследованные пациенты были разделены на две группы в зависимости от диагностированного миокардита: пациенты без признаков миокардита и пациенты с миокардитом. Установлено, что в группе пациентов с диагностированным миокардитом наблюдалось повышенное содержание СРБ, IGF-1R, IL-6 и IL-10, TNFa по сравнению с группой пациентов без миокардита. Средние концентрации NT-proBNP и sST2 в обеих группах не различались. При последующем визите через год наблюдалось снижение содержания СРБ, NT-proBNP, IL-6 в обеих группах. В группе больных миокардитом наблюдалось повышение содержания sST2, IGF-1R, IL-10. Таким образом, проведенное в динамике исследование выявило достоверные различия в изменении сывороточной активности про- и противовоспалительных цитокинов и биомаркеров сердечно-сосудистого риска у пациентов с декомпенсированной сердечной недостаточностью с систолической дисфункцией при диагностированном миокардите и при его отсутствии. </p></abstract><trans-abstract xml:lang="en"><p>The development and progression of heart failure is associated with a variety of pathophysiological mechanisms, of particular interest is the study of the inflammatory response as a fundamental link in the pathogenesis of CHF and its main component – decompensation. An open, non-randomized, prospective study was carried out to evaluate the clinical and morphological features of subclinical inflammation in patients with acute decompensation of ischemic chronic heart failure with a reduced ejection fraction. The study included 25 patients with decompensated ischemic CHF with left ventricular ejection fraction &lt; 40% aged 35 to 75 years (60.12±9.3 y. o.). In this study the dynamics of the serum content of C-reactive protein (CRP), N-terminal fragment of the brain natriuretic peptide precursor protein (NT-proBNP), soluble ST2(sST2), insulin-like growth factor-1 receptor (IGF-1R), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-α (TNFα) was performed by multiplex immunoassay using the FLEXMAP 3D. All studied patients were divided into two groups depending on the diagnosed myocarditis: patients with no signs of myocarditis and patients with myocarditis. It was found that in the group of patients with diagnosed myocarditis there was an increased content of CRP, IGF-1R, IL-6 and IL-10, TNFα compared to the group of patients without myocarditis. The median concentrations of the NT-proBNP and sST2 in both groups did not differ. At the follow-up visit a year later, there was a decrease in the content of CRP, NT-proBNP, IL-6 in both groups. In the group of patients with myocarditis, an increase in the content of sST2, IGF-1R, IL-10 was observed. Thus, the study carried out in dynamics revealed significant differences in the degree of changes in the serum activity of pro- and anti-inflammatory cytokines and biomarkers of cardiovascular risk in patients with decompensated heart failure with systolic dysfunction with diagnosed myocarditis and in its absence. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>воспаление</kwd><kwd>цитокины</kwd><kwd>биомаркеры</kwd><kwd>сердечная недостаточность</kwd><kwd>миокардит</kwd></kwd-group><kwd-group xml:lang="en"><kwd>inflammation</kwd><kwd>cytokines</kwd><kwd>biomarkers</kwd><kwd>heart failure</kwd><kwd>myocarditis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Gennadinik A.G., Nelaeva A.A. The role of insulin-like growth factor-I in metabolism, regulation of cell renewal and aging processes. Obesity and Metabolism, 2010, no. 2, pp. 10-15. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Gennadinik A.G., Nelaeva A.A. The role of insulin-like growth factor-I in metabolism, regulation of cell renewal and aging processes. Obesity and Metabolism, 2010, no. 2, pp. 10-15. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Grakova E.V., Teplyakov A.T., Kopyeva K.V., Akhmedov Sh.D., Ogurkova O.N., Soldatenko M.V. Prediction role of a novel biomarker ST2 in risk assessment of adverse cardiovascular events in chronic heart failure with preserved and intermediate ejection fraction after myocardial revascularization. Cardiovascular Therapy and Prevention, 2018, Vol. 17, no. 5, pp. 40-46. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Grakova E.V., Teplyakov A.T., Kopyeva K.V., Akhmedov Sh.D., Ogurkova O.N., Soldatenko M.V. Prediction role of a novel biomarker ST2 in risk assessment of adverse cardiovascular events in chronic heart failure with preserved and intermediate ejection fraction after myocardial revascularization. Cardiovascular Therapy and Prevention, 2018, Vol. 17, no. 5, pp. 40-46. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Grakova E.V., Kopieva K.V., Teplyakov A.T., Ogurkova O. N., Soldatenko M. V., Garganeeva A. A. Clinical use of the new biomarker ST2 in patients with chronic heart failure of ischemic genesis: an exercise test. Cardiovascular Therapy and Prevention, 2019, Vol. 18, no. 4, pp. 12-18. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Grakova E.V., Kopieva K.V., Teplyakov A.T., Ogurkova O. N., Soldatenko M. V., Garganeeva A. A. Clinical use of the new biomarker ST2 in patients with chronic heart failure of ischemic genesis: an exercise test. Cardiovascular Therapy and Prevention, 2019, Vol. 18, no. 4, pp. 12-18. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Grigoryan S.V., Adamyan K.G., Azarapetyan L.G. The role of inflammatory markers in atrial fibrillation: a review. Cardiovascular Therapy and Prevention, 2012, Vol. 11, no. 5, pp. 74-78. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Grigoryan S.V., Adamyan K.G., Azarapetyan L.G. The role of inflammatory markers in atrial fibrillation: a review. Cardiovascular Therapy and Prevention, 2012, Vol. 11, no. 5, pp. 74-78. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kamardinov D.Kh., Songurov R.N., Ioshina V.I., Buziashvili Yu.I. Soluble ST2 – as a biomarker, risk stratification tool, and therapeutic target in patients with chronic heart failure. Cardiology, 2020, Vol. 60, no. 2, pp. 111-121. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Kamardinov D.Kh., Songurov R.N., Ioshina V.I., Buziashvili Yu.I. Soluble ST2  – as a biomarker, risk stratification tool, and therapeutic target in patients with chronic heart failure. Cardiology, 2020, Vol. 60, no. 2, pp. 111-121. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kruchinkina E.V., Ryabova T.R., Rogovskaya Yu.V., Batalov R.E., Ryabov V.V. The incidence and profile of cardiotropic viral agents in the myocardium in patients with decompensated chronic heart failure with systolic dysfunction of ischemic origin. Siberian Medical Journal, 2017, Vol. 32, no.1, pp. 46-49. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Kruchinkina E.V., Ryabova T.R., Rogovskaya Yu.V., Batalov R.E., Ryabov V.V. The incidence and profile of cardiotropic viral agents in the myocardium in patients with decompensated chronic heart failure with systolic dysfunction of ischemic origin. Siberian Medical Journal, 2017, Vol. 32, no.1, pp. 46-49. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kruchinkina E.V., Ryabov V.V. Immune response in decompensation of ischemic chronic heart failure. Russian Journal of Cardiology, 2018, Vol. 1, no. 153, pp. 72-77. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Kruchinkina E.V., Ryabov V.V. Immune response in decompensation of ischemic chronic heart failure. Russian Journal of Cardiology, 2018, Vol. 1, no. 153, pp. 72-77. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Serik S.A., Chenchik T.A., Serdobinskaya-Kanivets E.N., Bondar T.N. Interleukin-10 and pro / antiinflammatory cytokine balance in heart failure in patients with type 2 diabetes mellitus. Ukrainian Therapeutic Journal, 2012, no. 3-4, pp. 58-63. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Serik S.A., Chenchik T.A., Serdobinskaya-Kanivets E.N., Bondar T.N. Interleukin-10 and pro / antiinflammatory cytokine balance in heart failure in patients with type 2 diabetes mellitus. Ukrainian Therapeutic Journal, 2012, no. 3-4, pp. 58-63. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zakirova A.N., Fatkullina E.Z., Zakirova N.E., Zhamalov L.M. Insulin-like growth factor-1 and myocardial remodeling in patients with arterial hypertension and metabolic syndrome. Rational Pharmacotherapy in Cardiology, 2015, Vol. 11, no. 5, pp. 489-495. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Zakirova A.N., Fatkullina E.Z., Zakirova N.E., Zhamalov L.M. Insulin-like growth factor-1 and myocardial remodeling in patients with arterial hypertension and metabolic syndrome. Rational Pharmacotherapy in Cardiology, 2015, Vol. 11, no. 5, pp. 489-495. (In Russ.)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
